Sign in
CompletedPhase 1

Drug Interaction Study on Linaprazan Glurate Capsules

Key facts

Who runs it
Jiangsu Sinorda Biomedicine Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
56 people enrolled
Started
8 Sept 2025
Ended
15 Dec 2025
Type of study
Interventional, 3 groups
Treatments tested
  • Linaprazan Glurate Capsules
  • Bismuth Potassium Citrate Capsules
  • Amoxicillin Capsules
  • Clarithromycin tablets
  • Esomeprazole Magnesium Enteric-coated Tablets
Record updated
6 January 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Age range: 18 to 55 years old (including 18 and 55)
  • Male weight ≥50.0 kg, female weight ≥45.0 kg; Body Mass Index (BMI) between 19.0 and 26.0 kg/m²(including critical value); BMI=weight/height2 (m2)
  • Part 1 Study and Part 2 Study:; Part 1: Subjects must be Helicobacter pylori-negative at screening; Part 2: Subjects must be Helicobacter pylori-positive at screening
  • From signing informed consent until 3 months after study completion, subjects must: Implement appropriate and effective contraception to prevent pregnancy (applies to subject or partner); Refrain from sperm donation or egg donation plans
  • Subjects must fully comprehend the trial content, voluntarily participate in the trial, Provide written informed consent

Who cannot take part

  • Subjects with use of any investigational product within 3 months prior to screening
  • Subjects with use within 30 days prior to screening of Prescription drugs, Over-the-counter ,OTC) medications, Herbal medicines, Dietary supplements
  • Subjects with major surgery within 3 months prior to screening,and planned surgery during trial participation
  • Subjects who have used illicit drugs within the 3 months prior to screening, or have a history of drug abuse within the past 12 months, or whose urine drug abuse screening test result is positive
  • Subjects who regularly consumed alcohol within the 3 months prior to screening (i.e., consuming more than 14 standard units per week; 1 unit = 360mL of beer, or 45mL of 40% spirits, or 150mL of wine), or who are unwilling to abstain from alcohol or any alcohol-containing products for 48 hours prior to dosing and during the trial, or whose alcohol breath test result is positive
  • Subjects who smoked an average of >5 cigarettes per day within the 30 days prior to screening; or who cannot guarantee abstinence from smoking from the signing of the informed consent form until the end of the study
  • Subjects who have been vaccinated within the 3 months prior to screening or plan to be vaccinated during the trial period
  • Subjects who consumed excessive amounts of tea, coffee, or caffeinated beverages (more than 8 cups per day; 1 cup = 250mL) within the 4 weeks prior to screening
  • Subjects who consumed special diets (including pitaya, mango, grapefruit, pomelo, lime, starfruit, or foods/beverages prepared from them, or any caffeinated foods/beverages, alcoholic beverages, or other foods/beverages known to affect drug absorption, distribution, metabolism, or excretion) within 48 hours prior to the first dose
  • Subjects with history of diseases in the following systems (also investigator-determined as ineligible): Central nervous system, Cardiovascular system, Respiratory system, Digestive system, Endocrine system, Immune system, Neurological/Psychiatric systems, Hematologic/Lymphatic systems, Musculoskeletal system
  • Gastrointestinal/Surgical History: History of gastrointestinal diseases or surgeries including:Gastric surgery (except pyloromyotomy for infantile pyloric stenosis), Cholecystectomy, Vagotomy, Bowel resection, Any surgery potentially affecting GI motility, pH, or absorption, Conditions impacting drug ADME: Dysphagia, Vomiting, Severe diarrhea
  • Infectious Disease Screening: Positive results for any at screening: Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), Treponema pallidum antibody (TP-Ab)
  • Subjects who are intolerant to venipuncture, have difficulty with blood collection, or have a history of needle or blood phobia/syncope
  • Subjects known as Hypersensitivity History: Known allergy to: Linaprazan Glurate capsules, Esomeprazole (Part 2 only), Penicillin, Macrolide antibiotics, Any component of bismuth potassium citrate;History of severe immediate hypersensitivity to: Other macrolide antibiotics, β-lactam agents (e.g., cephalosporins, carbapenems, monobactams),Multiple drug hypersensitivity (e.g., allergic reactions to ≥2 medications/foods)
  • Clinically Significant Abnormalities at Screening: Abnormalities deemed clinically significant by investigators based on: Medical history review, Vital signs, Physical examination, 12-lead ECG, Laboratory tests: Complete blood count (CBC), Blood chemistry, Urinalysis, Coagulation tests
  • Subjects with Penicillin sodium skin test positivity during screening
  • Subjects with use of potassium-competitive acid blockers (P-CABs) within 3 months prior to screening
  • Cardiac Abnormalities: Clinically significant ECG abnormality history, Family history of Long QT Syndrome (grandparents, parents, siblings), Screening QTcF prolongation: 450 msec in males, 470 msec in females
  • Subjects with blood donation (whole blood/component) ≥400 mL within 3 months (excluding menstrual loss),Blood transfusion or blood product use within 3 months
  • Pregnant or lactating women
  • Subjects with special dietary requirements who cannot comply with the standardized diet, or who have difficulty swallowing
  • Subjects deemed unsuitable for participation by the investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a drug-drug interaction (DDI) investigation involving Linaprazan Glurate capsules and a combination of clarithromycin tablets, amoxicillin capsules, and bismuth potassium citrate capsules. The study plan is divided into two parts: one involving Hp-negative healthy subjects and the other involving Hp-positive subjects.

The 3 groups in the trial

  • Linaprazan Glurate Capsules 50mg BID, consecutive 7-day dosing per periodTreatment being tested

    Glurate Capsules Capsules 50mg, BID, consecutive 7-day dosing per period in Part 1.

    Treatment: Linaprazan Glurate Capsules, Amoxicillin Capsules, and Clarithromycin tablets

  • Linaprazan Glurate Capsules 50mg BID, consecutive 14-day dosingTreatment being tested

    Linaprazan Glurate Capsules 50mg BID, consecutive 14-day dosing in part 2.

    Treatment: Linaprazan Glurate Capsules, Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, and Clarithromycin tablets

  • Esomeprazole Magnesium Enteric-coated Tablets 20mg BID, consecutive 14-day dosing.Treatment being tested

    Esomeprazole Magnesium Enteric-coated Tablets 20mg, BID in Part 2.

    Treatment: Bismuth Potassium Citrate Capsules, Amoxicillin Capsules, Clarithromycin tablets, and Esomeprazole Magnesium Enteric-coated Tablets

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Drug Interaction Study on Linaprazan Glurate Capsules, Clarithromycin Tablets, Amoxicillin Capsules, and Bismuth Potassium Citrate Capsules
Record updated
6 January 2026